Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 175 citing articles:

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Jingyue Wang, Quanwei Wang, Xinyu Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 120
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse, et al.
American Heart Journal (2023) Vol. 267, pp. 1-11
Open Access | Times Cited: 81
Incretin hormones and type 2 diabetes
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 76
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 73
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 1, pp. 25-45
Open Access | Times Cited: 59
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 784-796
Closed Access | Times Cited: 56
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 54
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Matthias H. Tschöp, Rubén Nogueiras, Bo Åhrén
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1796-1808
Open Access | Times Cited: 51
Glucagon‐like peptide agonists: A prospective review
Zamara Mariam, Sarfaraz K. Niazi
Endocrinology Diabetes & Metabolism (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 47
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database
Mansour Tobaiqy, Hajer Elkout
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 2, pp. 488-495
Open Access | Times Cited: 31
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang
The Kaohsiung Journal of Medical Sciences (2024) Vol. 40, Iss. 3, pp. 212-220
Open Access | Times Cited: 18
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 17
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials
Ellen M. Apperloo, Katherine R. Tuttle, Imre Pávó, et al.
Diabetes Care (2025)
Closed Access | Times Cited: 3
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3094-3094
Open Access | Times Cited: 35
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
Huzaifa Ul Haq Ansari, Shurjeel Uddin Qazi, Faiza Sajid, et al.
Endocrine Practice (2023) Vol. 30, Iss. 2, pp. 160-171
Closed Access | Times Cited: 35
Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 1, pp. 126-143
Open Access | Times Cited: 33
Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
André Scheen
Annales d Endocrinologie (2023) Vol. 84, Iss. 2, pp. 316-321
Closed Access | Times Cited: 32
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
Ildiko Lingvay, Ofri Mosenzon, Katelyn Brown, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 29
Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies
Nilanjan Ghosh, Leena Chacko, Hiranmoy Bhattacharya, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1126-1126
Open Access | Times Cited: 29
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Sydney S. Wilbon, Mikhail G. Kolonin
Cells (2023) Vol. 13, Iss. 1, pp. 65-65
Open Access | Times Cited: 27
Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
Sudhir Pandey, Supachoke Mangmool, Warisara Parichatikanond
Pharmaceuticals (2023) Vol. 16, Iss. 6, pp. 836-836
Open Access | Times Cited: 25
Tirzepatida: Un Avance Revolucionario en el Tratamiento de la Diabetes Mellitus Tipo 2 y la Obesidad
Mariana Chávez
Revista Veritas de Difusão Cientifica. (2023) Vol. 4, Iss. 1, pp. 96-110
Open Access | Times Cited: 25
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Konstantinos Stefanakis, Michail Kokkorakis, Christos S. Mantzoros
Metabolism (2024), pp. 156057-156057
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top